What MSA Safety's 22x Multiple Is Really Paying For

MSA Safety made the news on an earnings beat: adjusted profit came in 12% above the estimate and the stock jumped 10% in a single day. Then it quietly gave most of that back. Six weeks later the shares are down about 6% over the past month and sitting just under their 50-day average, and this Thursday the company walks onto the Jefferies industrials stage — CEO Steve Blanco and CFO Julie Beck, as usual — to talk about "growth drivers" one more time.

That timing is the whole story. After a strong +13% year so far and a clear beat, the question in front of you is no longer "did MSA do well." It's whether 22x earnings is still a fair price for a company that makes gas detectors and hard hats. A conference transcript won't answer that. The factor stack will, and the answer hinges on one thing: what the multiple is actually paying for — growth, or quality. Those two things justify very different prices, and they are not the same story.

The quality is real, and it's measurable

Strip away the price action and MSA's business is a quality business in the plainest sense. Over the last twelve months it ran a gross margin near 47%, an operating margin just over 20% on a GAAP basis, and a 24% EBITDA margin — turning about 16% of revenue into free cash flow on just ~$50 million of capital, or 2.6% of sales. Return on invested capital sits near 16%, return on equity near 24%.

For a manufacturer, that is an unusually asset-light, high-conversion operation. You are not running a plant-heavy factory to print this cash. This is the part of the report card that earns a premium multiple, because it is durable and it does not show up in a one-quarter beat. It is why MSA does not trade at the 10x of a low-growth defensive name, and it is the entire reason the 22x is even in the conversation.

But the multiple is a quality bill, not a growth bill

Here is where the comparison does the real work. Put MSA's ~22x trailing earnings — and ~15x EBITDA — next to the names that anchor it on the industrial screen:

• 3M (MMM): ~28x earnings, ~15.5x EBITDA
• W.W. Grainger (GWW): ~32x earnings, ~20.6x EBITDA
• Solventum (SOLV): ~10x earnings, ~7.6x EBITDA

On EBITDA, MSA trades right around diversified-industrial 3M, about a quarter below the MRO-distribution franchise Grainger, and about double the low-growth health-care spin Solventum. Be clear about Solventum before you use it: it is a different animal — a defensive health business with thinner margins and slower growth, so its 10x reflects different economics, not a verdict that MSA is overpriced. It is the cheap end of the set, not a peer in the safety business.

What the set shows is that MSA's 22x is not a growth multiple. Management guides sales growth for 2026 — a respectable number, but not a premium one. Run a 22x multiple against the ~24% earnings growth of the last couple of quarters and the trailing price-to-growth lands near 1.5 — unremarkable for a quality name. Run that same 22x against the mid-single-digit growth management is actually guiding forward, and the premium is a lot harder to defend. The forward number flatters things a little — on consensus for the coming year (roughly $9.30 a share) the stock is closer to 20x than the trailing 22x. But directionally, the market is paying MSA for the profitability, not for an accelerating top line. That is the distinction that matters, and it is the one the conference headline hides.

The report card is improving; the tape is cooling

Trajectory matters as much as level, and here MSA is split. The fundamental grade is moving the right way: free cash flow up ~40% year over year, the quarter's adjusted earnings up 24%, and margins expanding sharply in the latest report alone — gross margin 49.5%, up 290 basis points year over year. That is the improving-report-card story, and a stock moving from good to better is usually more actionable than one already at an A+ with nowhere left to go.

The momentum grade is moving the other way. After the 10% pop on the beat, MSA has retraced ~6% over the last month, sits below its 50-day average, and its 14-day RSI is near 38 — soft, not broken. And the cross-check lands where the numbers point: AInvest's aggregate signal has the consensus at Hold, not Buy. Quality plus a Hold, after a +13% year, is not "buy the dip." It is the easy part of the move being done.

Where it sits in a book

So what does the factor stack say to do? MSA is a quality, defensive-industrial holding — the let-winners-run sleeve, not a fresh aggressive add at 22x after a strong year. You hold it for the margin quality and the cash conversion, and you accept that the growth is mid-single-digit, which is exactly why it does not trade like the premium franchises it sits under. The read changes on one of two things: growth re-accelerating meaningfully above mid-single-digit organic — the detection and fall-protection lines plus the MSA+ connected-solutions attach are the lever management keeps pointing to — or the multiple compressing toward the middle of this set on a deeper pullback, which is where the quality-to-price gap gets comfortable again. Until one of those shows up, MSA is a name you keep on the list with respect, not a name you chase off a conference-call headline.